Keyword: Tecfidera

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.

Biogen's MS business has been treading water and its top-selling Tecfidera might face early generics. But now a follow-up med has nabbed FDA approval.

Tecfidera has managed to keep growing sales as competition in multiple sclerosis intensified. Now, Biogen is touting data its new rivals can't match.

After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.

Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.

Rejected in 2011, Mavenclad won FDA approval with a label that's not ideal—but that doesn't necessarily hurt its blockbuster odds, says one analyst.

With the aducanumab flop, shareholders are questioning management’s strategy—and an uncertain pipeline isn’t helping, either.

Biogen has been working hard to build out its pipeline, but as that effort plays out, the biotech faces a new patent challenge to its top moneymaker.

After releasing strong earnings, Biogen's executives did their best to reassure analysts that the success of the pipeline won't rely solely on Alzheimer's.